Literature DB >> 29146605

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.

Emanuele Pontali1, Giovanni Sotgiu2, Simon Tiberi3,4, Lia D'Ambrosio5,6, Rosella Centis5, Giovanni B Migliori7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29146605     DOI： 10.1183/13993003.01462-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  30 in total

1.  Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress.

Authors:  Alberto L Garcia-Basteiro; Ernie Wong; Pouline M Van Oort; Catia Cilloniz; Giovanni Battista Migliori; Aran Singanayagam
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

2.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

3.  Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.

Authors:  Fangchao Liu; Jingtao Gao; Mengqiu Gao; Yuhong Liu; Wei Shu; Li Xie; Yuxian Sun; Lijie Zhang; Liang Li; Yu Pang
Journal:  Antimicrob Agents Chemother       Date:  2022-09-01       Impact factor: 5.938

Review 4.  Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians.

Authors:  Matt Mason; Eric Gregory; Keith Foster; Megan Klatt; Sara Zoubek; Albert J Eid
Journal:  Open Forum Infect Dis       Date:  2022-06-15       Impact factor: 4.423

5.  A new era for treatment of drug-resistant tuberculosis.

Authors:  Neel R Gandhi; James C M Brust; N Sarita Shah
Journal:  Eur Respir J       Date:  2018-10-04       Impact factor: 16.671

6.  Mode-of-action profiling reveals glutamine synthetase as a collateral metabolic vulnerability of M. tuberculosis to bedaquiline.

Authors:  Zhe Wang; Vijay Soni; Gwendolyn Marriner; Takushi Kaneko; Helena I M Boshoff; Clifton E Barry; Kyu Y Rhee
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-09       Impact factor: 11.205

7.  QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.

Authors:  Kelly E Dooley; Susan L Rosenkranz; Francesca Conradie; Laura Moran; Richard Hafner; Florian von Groote-Bidlingmaier; Javier R Lama; Justin Shenje; Jorge De Los Rios; Kyla Comins; Joel Morganroth; Andreas H Diacon; Yoninah S Cramer; Kathleen Donahue; Gary Maartens
Journal:  Lancet Infect Dis       Date:  2021-02-12       Impact factor: 71.421

8.  Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.

Authors:  Norbert Ndjeka; Jonathon R Campbell; Graeme Meintjes; Gary Maartens; H Simon Schaaf; Jennifer Hughes; Xavier Padanilam; Anja Reuter; Rodolfo Romero; Farzana Ismail; Martin Enwerem; Hannetjie Ferreira; Francesca Conradie; Kogieleum Naidoo; Dick Menzies
Journal:  Lancet Infect Dis       Date:  2022-05-02       Impact factor: 71.421

Review 9.  Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.

Authors:  Klaudia T Angula; Lesetja J Legoabe; Richard M Beteck
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13

10.  WHO consolidated guidelines on tuberculosis 2020 moving toward fully oral regimen: Should country act in hurry?

Authors:  Nirmal Kumar Jain
Journal:  Lung India       Date:  2021 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.